Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Stem Cell Res Ther ; 9(1): 152, 2018 06 06.
Article in English | MEDLINE | ID: mdl-29871694

ABSTRACT

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a motor neuron (MN) disease characterized by the loss of MNs in the central nervous system. As MNs die, patients progressively lose their ability to control voluntary movements, become paralyzed and eventually die from respiratory/deglutition failure. Despite the selective MN death in ALS, there is growing evidence that malfunctional astrocytes play a crucial role in disease progression. Thus, transplantation of healthy astrocytes may compensate for the diseased astrocytes. METHODS: We developed a good manufacturing practice-grade protocol for generation of astrocytes from human embryonic stem cells (hESCs). The first stage of our protocol is derivation of astrocyte progenitor cells (APCs) from hESCs. These APCs can be expanded in large quantities and stored frozen as cell banks. Further differentiation of the APCs yields an enriched population of astrocytes with more than 90% GFAP expression (hES-AS). hES-AS were injected intrathecally into hSOD1G93A transgenic mice and rats to evaluate their therapeutic potential. The safety and biodistribution of hES-AS were evaluated in a 9-month study conducted in immunodeficient NSG mice under good laboratory practice conditions. RESULTS: In vitro, hES-AS possess the activities of functional healthy astrocytes, including glutamate uptake, promotion of axon outgrowth and protection of MNs from oxidative stress. A secretome analysis shows that these hES-AS also secrete several inhibitors of metalloproteases as well as a variety of neuroprotective factors (e.g. TIMP-1, TIMP-2, OPN, MIF and Midkine). Intrathecal injections of the hES-AS into transgenic hSOD1G93A mice and rats significantly delayed disease onset and improved motor performance compared to sham-injected animals. A safety study in immunodeficient mice showed that intrathecal transplantation of hES-AS is safe. Transplanted hES-AS attached to the meninges along the neuroaxis and survived for the entire duration of the study without formation of tumors or teratomas. Cell-injected mice gained similar body weight to the sham-injected group and did not exhibit clinical signs that could be related to the treatment. No differences from the vehicle control were observed in hematological parameters or blood chemistry. CONCLUSION: Our findings demonstrate the safety and potential therapeutic benefits of intrathecal injection of hES-AS for the treatment of ALS.


Subject(s)
Amyotrophic Lateral Sclerosis/genetics , Amyotrophic Lateral Sclerosis/metabolism , Astrocytes/metabolism , Human Embryonic Stem Cells/metabolism , Injections, Spinal/methods , Superoxide Dismutase-1/genetics , Amyotrophic Lateral Sclerosis/pathology , Animals , Disease Models, Animal , Humans , Mice , Rats , Superoxide Dismutase-1/metabolism
2.
Cell Host Microbe ; 20(4): 458-470, 2016 Oct 12.
Article in English | MEDLINE | ID: mdl-27736644

ABSTRACT

Mounting an effective immune response, while also protecting tissue integrity, is critical for host survival. We used a combined genomic and proteomic approach to investigate the role of extracellular matrix (ECM) proteolysis in achieving this balance in the lung during influenza virus infection. We identified the membrane-tethered matrix metalloprotease MT1-MMP as a prominent host-ECM-remodeling collagenase in influenza infection. Selective inhibition of MT1-MMP protected the tissue from infection-related structural and compositional tissue damage. MT1-MMP inhibition did not significantly alter the immune response or cytokine expression. The available flu therapeutic Oseltamivir did not prevent lung ECM damage and was less effective than anti-MT1-MMP in influenza virus Streptococcus pneumoniae coinfection paradigms. Combination therapy of Oseltamivir with anti-MT1-MMP showed a strong synergistic effect and resulted in complete recovery of infected mice. This study highlights the importance of tissue resilience in surviving infection and the potential of such host-pathogen therapy combinations for respiratory infections.


Subject(s)
Extracellular Matrix/metabolism , Lung/pathology , Matrix Metalloproteinase 14/metabolism , Orthomyxoviridae Infections/pathology , Orthomyxoviridae/growth & development , Animals , Antiviral Agents/therapeutic use , Disease Models, Animal , Female , Gene Expression Profiling , Genomics , Lung/virology , Mice , Mice, Inbred C57BL , Orthomyxoviridae Infections/drug therapy , Orthomyxoviridae Infections/virology , Oseltamivir/therapeutic use , Protease Inhibitors/therapeutic use , Proteolysis , Proteome/analysis , Proteomics , Survival Analysis , Treatment Outcome
3.
Proc Natl Acad Sci U S A ; 113(39): 10884-9, 2016 09 27.
Article in English | MEDLINE | ID: mdl-27630193

ABSTRACT

It is well established that the expression profiles of multiple and possibly redundant matrix-remodeling proteases (e.g., collagenases) differ strongly in health, disease, and development. Although enzymatic redundancy might be inferred from their close similarity in structure, their in vivo activity can lead to extremely diverse tissue-remodeling outcomes. We observed that proteolysis of collagen-rich natural extracellular matrix (ECM), performed uniquely by individual homologous proteases, leads to distinct events that eventually affect overall ECM morphology, viscoelastic properties, and molecular composition. We revealed striking differences in the motility and signaling patterns, morphology, and gene-expression profiles of cells interacting with natural collagen-rich ECM degraded by different collagenases. Thus, in contrast to previous notions, matrix-remodeling systems are not redundant and give rise to precise ECM-cell crosstalk. Because ECM proteolysis is an abundant biochemical process that is critical for tissue homoeostasis, these results improve our fundamental understanding its complexity and its impact on cell behavior.


Subject(s)
Extracellular Matrix/metabolism , Matrix Metalloproteinase 13/metabolism , Matrix Metalloproteinase 1/metabolism , Proteolysis , Sequence Homology, Amino Acid , Animals , Cell-Matrix Junctions/metabolism , Collagen/metabolism , Collagen/ultrastructure , Elasticity , Extracellular Matrix/ultrastructure , Fibroblasts/metabolism , Humans , Imaging, Three-Dimensional , Principal Component Analysis , Rats , Rheology , Viscosity
4.
Cancer Res ; 76(14): 4249-58, 2016 07 15.
Article in English | MEDLINE | ID: mdl-27221706

ABSTRACT

Abnormal architectures of collagen fibers in the extracellular matrix (ECM) are hallmarks of many invasive diseases, including cancer. Targeting specific stages of collagen assembly in vivo presents a great challenge due to the involvement of various crosslinking enzymes in the multistep, hierarchical process of ECM build-up. Using advanced microscopic tools, we monitored stages of fibrillary collagen assembly in a native fibroblast-derived 3D matrix system and identified anti-lysyl oxidase-like 2 (LOXL2) antibodies that alter the natural alignment and width of endogenic fibrillary collagens without affecting ECM composition. The disrupted collagen morphologies interfered with the adhesion and invasion properties of human breast cancer cells. Treatment of mice bearing breast cancer xenografts with the inhibitory antibodies resulted in disruption of the tumorigenic collagen superstructure and in reduction of primary tumor growth. Our approach could serve as a general methodology to identify novel therapeutics targeting fibrillary protein organization to treat ECM-associated pathologies. Cancer Res; 76(14); 4249-58. ©2016 AACR.


Subject(s)
Breast Neoplasms/pathology , Collagen/metabolism , Extracellular Matrix/metabolism , Amino Acid Oxidoreductases/antagonists & inhibitors , Amino Acid Oxidoreductases/physiology , Animals , Antibodies, Monoclonal/immunology , Cell Line, Tumor , Cell Proliferation , Extracellular Matrix Proteins/analysis , Female , Mice , Mice, Inbred BALB C , Neoplasm Invasiveness , Tumor Microenvironment
5.
Int J Med Microbiol ; 303(8): 558-62, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23972615

ABSTRACT

Point mutations in the rpsL gene encoding ribosomal protein S12 can generate resistance to streptomycin, resulting in rapid emergence of resistance to this antibiotic during treatment. In this work, we demonstrate that while spontaneous rpsL mutants in Escherichia coli are resistant to streptomycin, they are more sensitive to the ribosome-targeting antibiotics chloramphenicol, tetracycline and erythromycin. Moreover, combinations of these antibiotics, even in low concentrations were enough to achieve complete growth inhibition of both wild type and rpsL mutant strains. Thus, combining ribosome-targeting drugs can be used as a new treatment strategy that may be effective against streptomycin-resistant ribosome mutants.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Escherichia coli Proteins/genetics , Escherichia coli/drug effects , Point Mutation , Ribosomal Proteins/genetics , Ribosomes/drug effects , Streptomycin/pharmacology , Chloramphenicol/pharmacology , Erythromycin/pharmacology , Escherichia coli/genetics , Escherichia coli/growth & development , Microbial Sensitivity Tests , Ribosomal Protein S9 , Ribosomes/genetics , Tetracycline/pharmacology
6.
Int J Antimicrob Agents ; 42(2): 129-32, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23664678

ABSTRACT

Streptomycin (Sm) was the first antibiotic used against Mycobacterium tuberculosis, the aetiological agent of tuberculosis (TB). However, point mutations in the rpsL gene can generate resistance to Sm, which is why spontaneous resistance to this antibiotic emerges so rapidly during treatment. Here we examine the interaction between Sm resistance and sensitivity to other ribosome-targeting antibiotics. Levels of resistance of rpsL mutants to the ribosome-affecting antibiotics chloramphenicol, tetracycline, gentamicin and erythromycin were tested, both singly and in combination. For this purpose, Mycobacterium smegmatis was used, which is commonly used in laboratory experiments as a model for TB. Generally, Sm-resistant mutants were as sensitive to the ribosome-affecting antibiotics as the wild-type strain. Combinations of different ribosome-affecting antibiotics were occasionally more potent than either of the single drugs, with better inhibition of both wild-type and mutant strains. Combining different ribosome-affecting drugs could represent an additional strategy in treating mycobacterial infections, including those resistant to newer drugs such as isoniazid or ethambutol.


Subject(s)
Anti-Bacterial Agents/pharmacology , Mutation, Missense , Mycobacterium smegmatis/drug effects , Mycobacterium smegmatis/genetics , Ribosomal Proteins/genetics , Ribosomes/drug effects , Ribosomes/genetics , Base Sequence , Drug Interactions , Microbial Sensitivity Tests , Molecular Sequence Data
SELECTION OF CITATIONS
SEARCH DETAIL
...